NO20054200L - Pyrazoler samt fremgangsmate for fremstilling derav - Google Patents
Pyrazoler samt fremgangsmate for fremstilling deravInfo
- Publication number
- NO20054200L NO20054200L NO20054200A NO20054200A NO20054200L NO 20054200 L NO20054200 L NO 20054200L NO 20054200 A NO20054200 A NO 20054200A NO 20054200 A NO20054200 A NO 20054200A NO 20054200 L NO20054200 L NO 20054200L
- Authority
- NO
- Norway
- Prior art keywords
- pyrazoles
- preparation
- well
- alk
- formula
- Prior art date
Links
- 150000003217 pyrazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44677703P | 2003-02-12 | 2003-02-12 | |
| PCT/US2004/004049 WO2004072033A2 (fr) | 2003-02-12 | 2004-02-12 | Pyrazoles et leurs methodes de fabrication et d'utilisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20054200D0 NO20054200D0 (no) | 2005-09-09 |
| NO20054200L true NO20054200L (no) | 2005-10-14 |
Family
ID=32869552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20054200A NO20054200L (no) | 2003-02-12 | 2005-09-09 | Pyrazoler samt fremgangsmate for fremstilling derav |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20060264440A1 (fr) |
| EP (1) | EP1596656A4 (fr) |
| JP (1) | JP2006517592A (fr) |
| KR (1) | KR20050101547A (fr) |
| CN (1) | CN1770980A (fr) |
| AR (1) | AR043184A1 (fr) |
| AU (1) | AU2004210855A1 (fr) |
| BR (1) | BRPI0407454A (fr) |
| CA (1) | CA2514382A1 (fr) |
| CL (1) | CL2004000234A1 (fr) |
| EA (1) | EA010161B1 (fr) |
| GE (1) | GEP20084391B (fr) |
| IS (1) | IS7966A (fr) |
| MX (1) | MXPA05008524A (fr) |
| NO (1) | NO20054200L (fr) |
| NZ (1) | NZ542289A (fr) |
| PL (1) | PL378072A1 (fr) |
| RS (1) | RS20050616A (fr) |
| UA (1) | UA82223C2 (fr) |
| WO (1) | WO2004072033A2 (fr) |
| ZA (1) | ZA200506408B (fr) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0313915D0 (en) * | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
| AU2005238270A1 (en) * | 2004-04-28 | 2005-11-10 | Arrow Therapeutics Limited | Morpholinylanilinoquinazo- line derivatives for use as antiviral agents |
| WO2006019965A2 (fr) * | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Inhibiteurs de la dipeptidyl peptidase |
| CA2578628A1 (fr) * | 2004-08-31 | 2006-03-09 | Biogen Idec Ma Inc. | Pyrimidinylpyrazoles utilises comme inhibiteurs de tgf-beta |
| EP1798229A4 (fr) * | 2004-09-07 | 2009-07-29 | Sankyo Co | Derive de biphenyle substitue |
| CA2584248A1 (fr) * | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Procede pour traiter des lesions vasculaires |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| CN103012254A (zh) | 2005-05-10 | 2013-04-03 | 英特芒尼公司 | 用于调节应激-活化蛋白激酶系统的吡啶酮衍生物 |
| GB0520475D0 (en) * | 2005-10-07 | 2005-11-16 | Arrow Therapeutics Ltd | Chemical compounds |
| AU2007204227B2 (en) * | 2006-01-11 | 2011-03-03 | Arrow Therapeutics Limited | Triazoloanilinopyrimidine derivatives for use as antiviral agents |
| CA2645583A1 (fr) * | 2006-03-20 | 2007-09-27 | F. Hoffman-La Roche Ag | Procedes d'inhibition des proteines kinase btk et syk |
| CN101062916B (zh) * | 2006-04-29 | 2012-12-26 | 中国人民解放军军事医学科学院毒物药物研究所 | 三取代1h-吡唑化合物、其制备方法、药物组合物及其制药用途 |
| WO2008009078A2 (fr) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | Dérivés de la quinazoline tri-substitués en 4,6-dl et en 2,4,6 utilisables pour traiter les infections virales |
| US8673929B2 (en) | 2006-07-20 | 2014-03-18 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections |
| RU2009106722A (ru) | 2006-07-28 | 2010-09-10 | Новартис АГ (CH) | 2,4-замещенные хиназолины в качестве ингибиторов липидной киназы |
| ES2538265T3 (es) | 2006-10-03 | 2015-06-18 | Genzyme Corporation | Anticuerpos contra TGF-beta para uso en el tratamiento de lactantes con riesgo de desarrollar displasia broncopulmonar |
| MX2009003157A (es) * | 2006-10-16 | 2009-04-03 | Pfizer Prod Inc | Pirazoliltienopiridinas terapeuticas. |
| JP5507045B2 (ja) | 2006-12-15 | 2014-05-28 | 石原産業株式会社 | アントラニルアミド系化合物の製造方法 |
| WO2009009059A1 (fr) * | 2007-07-09 | 2009-01-15 | Biogen Idec Ma Inc. | Composés spiro en tant qu'antagonistes du tgf-bêta |
| AP2010005167A0 (en) * | 2007-08-01 | 2010-02-28 | Pfizer | Pyrazole compounds and their use as RAF inhibitors |
| CL2009000904A1 (es) | 2008-04-21 | 2010-04-30 | Shionogi & Co | Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende. |
| MX2010012848A (es) | 2008-06-03 | 2011-03-01 | Intermune Inc | Compuestos y metodos para tratar trastornos inflamatorios y fibroticos. |
| EP2485731B1 (fr) | 2009-10-06 | 2016-05-11 | Millennium Pharmaceuticals, Inc. | Composes heterocycliques utilises comme inhibiteurs de pdk1 |
| MY165634A (en) * | 2010-12-01 | 2018-04-18 | Nissan Chemical Ind Ltd | Pyrazole compounds having therapeutic effect on multiple myeloma |
| KR101084729B1 (ko) | 2011-06-10 | 2011-11-22 | 재단법인 한국원자력의학원 | 이소옥사졸 유도체를 포함하는 ＴＧＦ-β 활성 저해용 조성물 |
| EP2737083A1 (fr) | 2011-07-27 | 2014-06-04 | INSERM (Institut National de la Santé et de la Recherche Scientifique) | Méthodes de diagnostic et de traitement du syndrome de myhre |
| MX2014004994A (es) | 2011-10-26 | 2014-08-27 | Seattle Children S Res Inst | Cisteamina en el tratamiento de enfermedad fibrotica. |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| MX2014014531A (es) * | 2012-05-31 | 2015-04-08 | Hoffmann La Roche | Derivados de aminoquinazolina y piridopirimidina. |
| EP2877466B1 (fr) * | 2012-07-26 | 2016-07-06 | F. Hoffmann-La Roche AG | Modulateurs benzisoxazole de la neurogénèse |
| AR092742A1 (es) * | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| JP6064062B2 (ja) | 2013-03-15 | 2017-01-18 | ファイザー・インク | Ａｍｐｋを活性化させるインダゾール化合物 |
| KR102373700B1 (ko) | 2014-04-02 | 2022-03-11 | 인터뮨, 인크. | 항섬유성 피리디논 |
| CU20180011A7 (es) | 2015-03-04 | 2018-06-05 | Gilead Sciences Inc | Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll |
| US10822337B2 (en) | 2015-04-01 | 2020-11-03 | Rigel Pharmaceuticals, Inc. | TGF-β inhibitorC |
| WO2016210292A1 (fr) | 2015-06-25 | 2016-12-29 | Children's Medical Center Corporation | Procédés et compositions se rapportant à l'expansion, l'enrichissement et la conservation de cellules souches hématopoïétiques |
| EP3939973A1 (fr) | 2015-07-06 | 2022-01-19 | Alkermes, Inc. | Inhibiteurs hétéro-halo d'histone désacétylase |
| WO2017007755A1 (fr) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc. | N-aminophényl-amides hétérocycliques en tant qu'inhibiteurs de l'histone désacétylase |
| DK3429603T3 (da) | 2016-03-15 | 2022-03-14 | Childrens Medical Center | Fremgangsmåder og sammensætninger vedrørende ekspansion af hæmatopoietiske stamceller |
| KR102412035B1 (ko) * | 2016-06-13 | 2022-06-22 | 젠플리트 테라퓨틱스 (상하이) 아이엔씨. | TGF-βRI 억제제인 벤조트리아졸에서 유도된 α,β-불포화 아미드계 화합물 |
| KR102434226B1 (ko) * | 2016-06-30 | 2022-08-19 | 한미약품 주식회사 | Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도 |
| ES2826748T3 (es) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
| US10370342B2 (en) | 2016-09-02 | 2019-08-06 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| CN108069955B (zh) * | 2016-11-14 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | 3-吡啶基-4-苯并噻唑基吡唑类衍生物、其制备方法及其在医药上的应用 |
| EP3539957A4 (fr) * | 2016-11-14 | 2020-05-13 | Jiangsu Hengrui Medicine Co., Ltd. | Dérivé de 3,4-bipyridyle pyrazole, procédé de préparation et application médicale associés |
| LT3570834T (lt) | 2017-01-11 | 2022-03-10 | Alkermes, Inc. | Bicikliniai histono deacetilazės inhibitoriai |
| KR20200037286A (ko) | 2017-08-07 | 2020-04-08 | 로딘 테라퓨틱스, 인크. | 히스톤 데아세틸라제의 비사이클릭 억제제 |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| EP3894401A2 (fr) | 2018-12-11 | 2021-10-20 | Theravance Biopharma R&D IP, LLC | Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5 |
| TW202415643A (zh) | 2018-12-12 | 2024-04-16 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
| WO2020201362A2 (fr) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes de prédiction et de prévention du cancer chez des patients ayant des lésions prémalignes |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| AU2020257301B2 (en) | 2019-04-18 | 2025-10-23 | The Johns Hopkins University | Substituted 2-amino-pyrazolyl-(1,2,4)triazolo(1,5a) pyridine derivatives and use thereof |
| TWI879779B (zh) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| EP4037772B1 (fr) * | 2019-10-03 | 2023-11-22 | Bristol-Myers Squibb Company | Indazole carboxamides en tant qu'inhibiteurs de kinase |
| IL293084A (en) | 2019-11-22 | 2022-07-01 | Theravance Biopharma R& D Ip Llc | Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors |
| KR20220107180A (ko) * | 2019-11-28 | 2022-08-02 | 오리고 바이오파마, 에스.엘. | 형질전환 성장 인자-베타 수용체 i/alk5의 억제제로서의 벤질아미드 유도체 |
| WO2021120890A1 (fr) | 2019-12-20 | 2021-06-24 | Novartis Ag | Dérivés pyrazolyle utiles en tant qu'agents anticancéreux |
| CN113620956B (zh) * | 2020-05-06 | 2023-06-13 | 赛诺哈勃药业（成都）有限公司 | 转化生长因子受体拮抗剂、其制备方法和应用 |
| CN114230565B (zh) * | 2020-09-09 | 2023-10-27 | 成都奥睿药业有限公司 | 5-取代吲哚3-酰胺衍生物及其制备方法和用途 |
| CN112759592A (zh) * | 2021-02-01 | 2021-05-07 | 无锡鸣鹭医药科技有限公司 | 一种6-碘[1,2,3]三唑并[1,5-a]吡啶的合成方法 |
| BR112023018593A2 (pt) * | 2021-03-18 | 2023-10-24 | Hoffmann La Roche | Processo |
| WO2024111626A1 (fr) * | 2022-11-25 | 2024-05-30 | カルナバイオサイエンス株式会社 | Nouveau dérivé de thiazole |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3940486A (en) * | 1971-05-10 | 1976-02-24 | Ciba-Geigy Corporation | Imidazole derivatives in the treatment of pain |
| US4302464A (en) * | 1980-10-16 | 1981-11-24 | Pfizer Inc. | Imidazolylpyridine therapeutic agents |
| US4686231A (en) * | 1985-12-12 | 1987-08-11 | Smithkline Beckman Corporation | Inhibition of 5-lipoxygenase products |
| US4925857A (en) * | 1989-03-22 | 1990-05-15 | Sterling Drug Inc. | Pyridinyl-1H-pyrazole-1-alkanamides as antiarrhythmic agents |
| JP2753659B2 (ja) * | 1990-09-03 | 1998-05-20 | 株式会社大塚製薬工場 | ピラゾール誘導体 |
| US5916891A (en) * | 1992-01-13 | 1999-06-29 | Smithkline Beecham Corporation | Pyrimidinyl imidazoles |
| IL104369A0 (en) * | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
| US5656644A (en) * | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
| DE4233713A1 (de) * | 1992-10-07 | 1994-04-14 | Bayer Ag | Substituierte 4,5-Dihydro-1-pyrazolcarbonsäureanilide |
| US5670527A (en) * | 1993-07-16 | 1997-09-23 | Smithkline Beecham Corporation | Pyridyl imidazole compounds and compositions |
| US5593991A (en) * | 1993-07-16 | 1997-01-14 | Adams; Jerry L. | Imidazole compounds, use and process of making |
| US5593992A (en) * | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
| US5486534A (en) * | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| GB9423460D0 (en) * | 1994-11-21 | 1995-01-11 | Merck Sharp & Dohme | Therapeutic agents |
| JP3734180B2 (ja) * | 1994-12-28 | 2006-01-11 | エーザイ株式会社 | 新規ピラゾール誘導体 |
| US5514505A (en) * | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
| US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
| US5739143A (en) * | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
| IL118544A (en) * | 1995-06-07 | 2001-08-08 | Smithkline Beecham Corp | History of imidazole, the process for their preparation and the pharmaceutical preparations containing them |
| WO1997001575A1 (fr) * | 1995-06-29 | 1997-01-16 | Fujisawa Pharmaceutical Co., Ltd. | Substance wf16616, procede de production et utilisation |
| US5792778A (en) * | 1995-08-10 | 1998-08-11 | Merck & Co., Inc. | 2-substituted aryl pyrroles, compositions containing such compounds and methods of use |
| US5837719A (en) * | 1995-08-10 | 1998-11-17 | Merck & Co., Inc. | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
| US5717100A (en) * | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| ZA9610687B (en) * | 1995-12-22 | 1997-09-29 | Smithkline Beecham Corp | Novel synthesis. |
| US5977103A (en) * | 1996-01-11 | 1999-11-02 | Smithkline Beecham Corporation | Substituted imidazole compounds |
| ZA97175B (en) * | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
| US5872136A (en) * | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
| US5854265A (en) * | 1996-04-03 | 1998-12-29 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
| US5883105A (en) * | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5939557A (en) * | 1996-04-03 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5880140A (en) * | 1996-04-03 | 1999-03-09 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
| AU708883B2 (en) * | 1996-06-10 | 1999-08-12 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
| US5854264A (en) * | 1996-07-24 | 1998-12-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| WO1998021199A2 (fr) * | 1996-11-12 | 1998-05-22 | Novartis Ag | Nouveaux herbicides |
| US5939439A (en) * | 1996-12-30 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| WO1998047892A1 (fr) * | 1997-04-24 | 1998-10-29 | Ortho-Mcneil Corporation, Inc. | Imidazoles substitues utilisables dans le traitement de maladies inflammatoires |
| KR20010012808A (ko) * | 1997-05-22 | 2001-02-26 | 윌리암스 로저 에이 | ｐ38 키나아제로서 4-아릴-3(5)-헤테로아릴 치환 피라졸 |
| JP2004515543A (ja) * | 2000-12-11 | 2004-05-27 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 有害無脊椎動物を防除するためのキナゾリノン類およびピリジニルピリミジノン類 |
| GB0102672D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| JP2004521901A (ja) * | 2001-02-02 | 2004-07-22 | グラクソ グループ リミテッド | Ｔｇｆ阻害剤としてのピラゾール |
| DE60203263T2 (de) * | 2001-02-02 | 2006-02-09 | Smithkline Beecham Corp. | Pyrazolderivate gegen tgf überexprimierung |
| DE10113000A1 (de) * | 2001-03-17 | 2002-09-19 | Bayerische Motoren Werke Ag | System aus Verbrennungsmotor und Brennstoffzelle |
| EP1382603B1 (fr) * | 2001-04-26 | 2008-07-23 | Eisai R&D Management Co., Ltd. | Compose azote a anneaux condenses possedant un groupe pyrazolyle et servant de substituant, et composition medicale le comprenant |
| HU228844B1 (en) * | 2001-05-24 | 2013-06-28 | Lilly Co Eli | Pyrrole derivatives and pharmaceutical compositions containing them |
| WO2003032731A1 (fr) * | 2001-10-15 | 2003-04-24 | E.I. Du Pont De Nemours And Company | Iminobenzoxazines, iminobenzthiazines et iminoquinazolines servant a lutter contre les parasites invertebres |
| AU2003260345A1 (en) * | 2002-07-31 | 2004-02-23 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| GB0217786D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| EP2165708A3 (fr) * | 2002-09-18 | 2010-07-28 | Pfizer Products Inc. | Nouveaux composés de pyrazole utilisés comme inhibiteurs du facteur de croissance transformant (TGF) |
| WO2004026302A1 (fr) * | 2002-09-19 | 2004-04-01 | Eli Lilly And Company | Procedes relatifs a l'inhibition du tgf-beta par le biais de pyrazoles substitues |
| GB0313915D0 (en) * | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
-
2004
- 2004-02-11 CL CL200400234A patent/CL2004000234A1/es unknown
- 2004-02-12 CA CA002514382A patent/CA2514382A1/fr not_active Abandoned
- 2004-02-12 CN CNA200480009623XA patent/CN1770980A/zh active Pending
- 2004-02-12 WO PCT/US2004/004049 patent/WO2004072033A2/fr not_active Ceased
- 2004-02-12 EA EA200501274A patent/EA010161B1/ru not_active IP Right Cessation
- 2004-02-12 GE GEAP20048973A patent/GEP20084391B/en unknown
- 2004-02-12 US US10/545,179 patent/US20060264440A1/en not_active Abandoned
- 2004-02-12 NZ NZ542289A patent/NZ542289A/en unknown
- 2004-02-12 KR KR1020057014781A patent/KR20050101547A/ko not_active Ceased
- 2004-02-12 JP JP2006503509A patent/JP2006517592A/ja active Pending
- 2004-02-12 EP EP04710613A patent/EP1596656A4/fr not_active Withdrawn
- 2004-02-12 MX MXPA05008524A patent/MXPA05008524A/es unknown
- 2004-02-12 RS YUP-2005/0616A patent/RS20050616A/sr unknown
- 2004-02-12 AU AU2004210855A patent/AU2004210855A1/en not_active Abandoned
- 2004-02-12 PL PL378072A patent/PL378072A1/pl not_active Application Discontinuation
- 2004-02-12 BR BR0407454-8A patent/BRPI0407454A/pt not_active IP Right Cessation
- 2004-02-13 AR ARP040100462A patent/AR043184A1/es unknown
- 2004-12-02 UA UAA200508633A patent/UA82223C2/uk unknown
-
2005
- 2005-07-29 IS IS7966A patent/IS7966A/is unknown
- 2005-08-11 ZA ZA200506408A patent/ZA200506408B/en unknown
- 2005-09-09 NO NO20054200A patent/NO20054200L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| GEP20084391B (en) | 2008-06-10 |
| CA2514382A1 (fr) | 2004-08-26 |
| ZA200506408B (en) | 2006-05-31 |
| UA82223C2 (uk) | 2008-03-25 |
| US20060264440A1 (en) | 2006-11-23 |
| EP1596656A2 (fr) | 2005-11-23 |
| EP1596656A4 (fr) | 2006-10-18 |
| NO20054200D0 (no) | 2005-09-09 |
| IS7966A (is) | 2005-07-29 |
| KR20050101547A (ko) | 2005-10-24 |
| RS20050616A (sr) | 2007-09-21 |
| AU2004210855A1 (en) | 2004-08-26 |
| WO2004072033A2 (fr) | 2004-08-26 |
| JP2006517592A (ja) | 2006-07-27 |
| BRPI0407454A (pt) | 2006-01-24 |
| CL2004000234A1 (es) | 2005-04-15 |
| CN1770980A (zh) | 2006-05-10 |
| WO2004072033A3 (fr) | 2005-03-17 |
| AR043184A1 (es) | 2005-07-20 |
| MXPA05008524A (es) | 2005-10-20 |
| EA010161B1 (ru) | 2008-06-30 |
| EA200501274A1 (ru) | 2006-02-24 |
| NZ542289A (en) | 2009-03-31 |
| PL378072A1 (pl) | 2006-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20054200L (no) | Pyrazoler samt fremgangsmate for fremstilling derav | |
| NO20051503L (no) | Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme. | |
| NO20044779L (no) | Tri-substituerte heteroarylforbindelser samt fremstilling og anvendelse derav | |
| MXPA05002442A (es) | Imidazolopiridinas y metodos para la elaboracion y uso de las mismas. | |
| CL2010000204A1 (es) | Compuestos intermediarios derivados de 4 amino-3-metoxibenzamida; compuesto intermediario n-{4-[4-(ciclopropilmetil)piperazin-1-il]ciclohexil}acetamida; compuesto intermediario 2-cloro-7-etil-7,8-dihidro-5-metil-8-(1-metiletil)-6(5h)-pteridinona, útiles en la preparación de dihidropteridinonas sustituidas (divisional sol. 2077-05). | |
| NL300933I2 (nl) | Letermovir | |
| AU2003281213A1 (en) | 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough | |
| BR0308243A (pt) | Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero | |
| TW200621753A (en) | Pyrimidinylimidazoles and methods of making and using the same | |
| JO2371B1 (en) | 4-phenyl-pyridine derivatives | |
| NO20055219L (no) | Nye forbindelser | |
| WO2005019190A3 (fr) | Composes d'aminofurazan utiles comme inhibiteurs de proteine-kinases | |
| NO20051100L (no) | Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer | |
| NO20045677L (no) | Inhibitorer av JAK- og CDK2-proteinkinaser | |
| NO20053470L (no) | Triazolopyridaziner som proteinkinase-inhibitorer | |
| NO20090910L (no) | Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister | |
| ATE413388T1 (de) | Muskarin antagonisten | |
| NO20062020L (no) | 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika | |
| WO2004091514A3 (fr) | Antagonistes des recepteurs de cgrp | |
| NO20062983L (no) | Sulfonamid-derivater for behandling av sykdommer | |
| DE602004018637D1 (de) | A2a-adenosinrezeptorantagonisten | |
| TW200621752A (en) | Pyrimidinylpyrazoles and methods of making and using the same | |
| NO20060020L (no) | 3-fluorpiperidiner som NMDA/NR2B-antagonister | |
| NO20061137L (no) | Cyklopropylderivater som NK3-reseptorantagonister | |
| EA200500803A1 (ru) | Антагонисты ccr1 для лечения воспалительных артритов, демиелинизационных воспалительных заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |